SLC16A1 and prostate carcinoma: Fiaschi et al. found that inhibition of MCT1 by α-cyano-4-hydroxycinnamate (CHC) or siRNA interference inevitably decreased the tumor volume and thereby restrained prostate carcinoma cell survival [102].